What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q4 Earnings

Core Insights - Analysts project Medtronic (MDT) will report quarterly earnings of $1.58 per share, an increase of 8.2% year over year, with revenues expected to reach $8.81 billion, up 2.6% from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their initial projections [1][2] Revenue Projections - The consensus estimate for 'Net Sales- World Wide Revenue- Diabetes' is $700.27 million, reflecting a year-over-year change of +6.1% [3] - 'Net Sales- World Wide Revenue- Neuroscience' is forecasted to reach $2.55 billion, indicating no change year over year [4] - 'Net Sales- World Wide Revenue- Cardiovascular' is expected to be $3.27 billion, showing a +4.6% change from the previous year [4] - 'Net Sales- World Wide Revenue- Medical Surgical' is estimated at $2.27 billion, with a year-over-year change of +3.1% [4] U.S. Revenue Estimates - 'Net Sales- U.S. Revenue' is projected at $4.49 billion, suggesting a +3.3% year-over-year change [5] - 'Net Sales- U.S. Revenue- Medical Surgical' is expected to reach $966.71 million, indicating a +1.3% change from the prior year [5] International Revenue Estimates - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is estimated at $363.81 million, reflecting a +2.5% change year over year [6] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is projected to be $346.44 million, indicating a +2.2% change [6] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is expected to be $1.02 billion, with a -0.5% change year over year [7] - 'Net Sales- ROW- Cardiovascular' is forecasted at $1.74 billion, showing a +3.3% change from the previous year [7] - 'Net Sales- ROW- Cardiovascular- Coronary & Peripheral Vascular' is projected to reach $383.12 million, indicating a +3.8% change [8] Stock Performance - Medtronic shares have returned +4.3% over the past month, compared to the Zacks S&P 500 composite's +9.8% change, with a Zacks Rank 3 (Hold) indicating expected performance in line with the overall market [8]